Last reviewed · How we verify
Baricitinib 4 MG
Baricitinib 4 MG is a Small molecule drug developed by University Hospital, Rouen. It is currently FDA-approved. Also known as: Baricitinib, Olumiant, JAK Inhibitor, for group B.
Baricitinib 4 MG is a small molecule inhibitor of the tyrosine-protein kinase JAK1. It is being studied in clinical trials for various conditions, including Systemic Lupus Erythematosus.
At a glance
| Generic name | Baricitinib 4 MG |
|---|---|
| Also known as | Baricitinib, Olumiant, JAK Inhibitor, for group B, Lopinavir/Ritonavir tablets 250 mg/bid |
| Sponsor | University Hospital, Rouen |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis (PHASE1)
- Baricitinib in the Treatment of New-onset Juvenile Dermatomyositis (MYOCIT) (PHASE2)
- Baricitinib for Reduction of HIV - CNS (PHASE2)
- Combination of Baricitinib and Anti-TNF in Rheumatoid Arthritis (PHASE3)
- Efficacy and Safety of Baricitinib in Sjogren's Syndrome (PHASE2)
- A Study on the Efficacy and Safety of JAK Inhibitors Versus Calcineurin Inhibitors as Initial Therapy for Interstitial Lung Disease Associated With Antisynthetase Syndrome (NA)
- Efficacy and Tolerance of Baricitinib, a JAK Inhibitor, in the Treatment of Refractory Non-infectious Non-anterior Uveitis (PHASE3)
- A Trial of Baricitinib in Patients With Cardiac Sarcoidosis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Baricitinib 4 MG CI brief — competitive landscape report
- Baricitinib 4 MG updates RSS · CI watch RSS
- University Hospital, Rouen portfolio CI
Frequently asked questions about Baricitinib 4 MG
What is Baricitinib 4 MG?
Who makes Baricitinib 4 MG?
Is Baricitinib 4 MG also known as anything else?
What development phase is Baricitinib 4 MG in?
Related
- Manufacturer: University Hospital, Rouen — full pipeline
- Also known as: Baricitinib, Olumiant, JAK Inhibitor, for group B, Lopinavir/Ritonavir tablets 250 mg/bid
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing